This invention provides, among other things, compounds useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus or treating a disease.

Compounds of the formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein, R.sup.1 is optionally substituted pyrazolyl, and R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X.sub.3 and/or a P2X.sub.2/3 receptor antagonists and methods of making the compounds.

Compounds of the formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein, R.sup.1 is optionally substituted pyrazolyl, and R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X.sub.3 and/or a P2X.sub.2/3 receptor antagonists and methods of making the compounds.

An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula:

##STR00001##

wherein each symbol is as defined in the specification, or a salt thereof.

An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: ##STR00001##
wherein each symbol is as defined in the specification, or a salt thereof.

An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: ##STR00001##
wherein each symbol is as defined in the specification, or a salt thereof.

The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

Compounds of the formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein, R.sup.1 is optionally substituted pyrazolyl, and R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X.sub.3 and/or a P2X.sub.2/3 receptor antagonists and methods of making the compounds.

The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is ##STR00001##
or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.